Houska Dental Clinic Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 1302 E Main St, Vermillion, SD 57069 Phone: 605-624-3031 Fax: 605-624-8084 |
Knutson Familty Dentistry Llp Dentist Medicare: Not Enrolled in Medicare Practice Location: 1714 E Cherry St, Vermillion, SD 57069 Phone: 605-624-6291 Fax: 605-624-9488 |
Vermillion Dental Health Dentist Medicare: Not Enrolled in Medicare Practice Location: 11 Court St, Vermillion, SD 57069 Phone: 605-624-2869 |
University Of South Dakota Dental Hygiene Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 414 E Clark St, 120 East Hall, Vermillion, SD 57069 Phone: 605-677-5582 Fax: 605-677-5638 |
Siouxland Dental Health- Vermillion Pllc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 117 E Cherry St, Vermillion, SD 57069 Phone: 605-624-0070 Fax: 605-624-4070 |
Heartland Smiles Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 117 E Cherry St, Vermillion, SD 57069 Phone: 605-624-0070 Fax: 605-624-4070 |
Kopf Dental Group Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 11 Court St, Vermillion, SD 57069 Phone: 605-624-8695 |
News Archive
Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study for ISIS-PTP1BRx, an antisense drug for the treatment of type 2 diabetes targeting protein tyrosine phosphatase-1B, PTP-1B.
The new influenza drug Xofluza, developed by the Japanese pharmaceutical company Shionogi, was approved for clinical use in Japan in February 2018.
"[P]articipants at a symposium held last week by the U.K. Consortium on AIDS and International Development warned that progress on HIV and tuberculosis (TB) vaccines could be jeopardized by the recent downturn in global health funding," BMJ reports.
Erythrocytes that have been stored for several weeks before use may not cause problems in patients who receive transfusions during noncardiac surgery, a large retrospective analysis suggests.
Tenet Healthcare Corporation today reported adjusted EBITDA of $298 million for the quarter ended March 31, 2010, an increase of $20 million, or 7.2 percent, as compared to $278 million for the first quarter of 2009. Net income attributable to common shareholders for the first quarter of 2010 was $88 million, or $0.17 per diluted share, compared to $44 million, or $0.09 per diluted share, excluding a gain of $134 million, or $0.28 per diluted share, in the first quarter of 2009 related to the early extinguishment of debt.
› Verified 9 days ago